Journal
JOURNAL OF NEUROSCIENCE RESEARCH
Volume 87, Issue 3, Pages 677-682Publisher
WILEY
DOI: 10.1002/jnr.21874
Keywords
apolipoprotein E; MCAO; neuroprotection
Categories
Funding
- NIA NIH HHS [AG 020473, R44 AG020473-05, R44 AG020473, R43 AG020473] Funding Source: Medline
Ask authors/readers for more resources
Apolipoprotein E (apoE) is the primary apolipoprotein synthesized in the brain in response to injury with known neuroprotective effects exerted through antioxidant, anti inflammatory, antiexcitotoxic, and neurotrophic mechanisms. We have previously demonstrated that COG1410, an apoE mimetic peptide, exerts neuroprotective and anti inflammatory effects in a murine model of traumatic brain injury (TBI). As in TBI, ischemia-reperfusion injury is a component of acute stroke, which displays a pharmacogenetic association with the APOE4 gene. Using an intraluminal middle cerebral occlusion (MCAO) model in rats, we found that a single intravenous injection of COG1410 at 120 min post-MCAO significantly improved vestibulomotor function, decreased poststroke locomotor asymmetry, and decreased infarct volume of the ipsilateral hemisphere. These results support further exploration of a novel apoE-mimetic peptide, COG1410, as a therapeutic treatment for stroke. (C) 2008 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available